Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March

Rhea-AI Summary

Crinetics Pharmaceuticals (Nasdaq: CRNX) announced management will participate in two investor conferences in March 2026. A fireside chat is scheduled at the TD Cowen Health Care Conference on March 4, 2026 at 1:50 p.m. ET and management will hold 1x1 meetings at both TD Cowen and Leerink on March 4 and March 11, 2026. Live and archived webcasts will be available on the company's Events & Presentations page at www.crinetics.com/events.

News Market Reaction

+1.09%

1 alert

+1.09% News Effect

On the day this news was published, CRNX gained 1.09%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the following two upcoming investor conferences:

TD Cowen 46^th Annual Health Care Conference, Boston, MA

Fireside chat on Wednesday, March 4, 2026 at 1:50 p.m. Eastern Time
Webcast link HERE
Management will be available for 1x1 meetings with investors on Wednesday, March 4, 2026

Leerink Annual Global Healthcare Conference, Miami, FL

Management will be available for 1x1 meetings with investors on Wednesday, March 11, 2026

The live and archived webcast will be accessible on the Events & Presentations page in the Investors section of the Crinetics’ website at www.crinetics.com/events.

If you are interested in arranging a 1x1 meeting with management, please contact your conference representative.

ABOUT CRINETICS PHARMACEUTICALS
Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties.

Crinetics’ lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment approved by the U.S. FDA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics’ deep pipeline of 10+ disclosed programs includes late-stage investigational candidate atumelnant, which is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, and CRN09682, a nonpeptide drug conjugate candidate that is being developed to treat SST2 expressing neuroendocrine tumors and other SST2 expressing solid tumors. Additional discovery programs address a variety of endocrine conditions such as neuroendocrine tumors, Graves’ disease (including Graves’ hyperthyroidism and Graves’ orbitopathy, or thyroid eye disease), polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications.

Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340

Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075

FAQ

When will Crinetics (CRNX) present at the TD Cowen 46th Annual Health Care Conference in 2026?

Crinetics will hold a fireside chat on March 4, 2026 at 1:50 p.m. ET. According to the company, management will also be available for 1x1 investor meetings that same day at the TD Cowen conference in Boston.

How can investors watch Crinetics (CRNX) webcasts for the March 2026 conferences?

Investors can view live and archived webcasts on the company's Events & Presentations page. According to the company, the webcasts will be posted at www.crinetics.com/events for on-demand access after each presentation.

Will Crinetics (CRNX) management be available for one-on-one meetings at the March 2026 conferences?

Yes. Management will be available for 1x1 meetings at both conferences on March 4 and March 11, 2026. According to the company, investors should contact their conference representative to arrange meetings.

What is the date for Crinetics (CRNX) investor meetings at the Leerink Annual Global Healthcare Conference?

Crinetics management will be available for 1x1 meetings on March 11, 2026 at the Leerink conference in Miami. According to the company, scheduling should be arranged through each investor's conference representative.

Where will the Crinetics (CRNX) fireside chat take place during TD Cowen conference?

The fireside chat is part of the TD Cowen 46th Annual Health Care Conference in Boston, MA on March 4, 2026 at 1:50 p.m. ET. According to the company, a webcast will also be provided for remote viewers.

How do I request a 1x1 meeting with Crinetics (CRNX) management for March 2026 events?

Contact your conference representative to request a 1x1 meeting with management at the TD Cowen or Leerink conferences. According to the company, meetings are coordinated through the conference organizers rather than directly via the company website.